Three well-described examples are detailed below, but a number of other studies demonstrating TF dysregulation in haematopoietic networks have been performed, for example TLX1 and TLX3 fusion oncoproteins down-regulating the Runx1 promoter in T-ALL [69], Pu.1 and Irf9 antagonism of miR-342 expression following ATRA exposure in APML cells [70], and CEBPβ binding to Irf4, Xbp1 and Blimp1 regulatory sites in myeloma cell lines [71]. This evidence concerns the gene TF and acute lymphoblastic leukemia.